ENSYSCE BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) of -$673.31 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease · last filed 2021-08-16
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|
| 2021-06-30 | -$673.31K 10-Q · filed 2021-08-16 | ||
| 2020-12-31 | -$2.45M 10-Q · filed 2021-08-16 | $10.00K 10-K/A · filed 2021-06-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |